# (19) World Intellectual Property Organization International Bureau





### (43) International Publication Date 16 May 2002 (16.05.2002)

### **PCT**

# (10) International Publication Number WO 02/38584 A1

(51) International Patent Classification7:

.....

C07J 71/00

- (21) International Application Number: PCT/EP01/12808
- (22) International Filing Date:

6 November 2001 (06.11.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

00124626.3

10 November 2000 (10.11.2000) El

- (71) Applicant (for all designated States except US): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH [DE/DE]; Byk-Gulden-Strasse 2, 78467 Konstanz (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): GUTTERER, Beate [DE/DE]; Allensbacher Str. 5, 78476 Allensbach (DE).

(74) Common Representative: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH; Byk-Gulden-Strasse 2, 78467 Konstanz (DE).

- (81) Designated States (national): AE, AL, AU, BA, BG, BR, CA, CN, CO, CU, CZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MK, MX, NO, NZ, PH, PL, RO, SG, SI, SK, UA, US, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



88584 AJ

(54) Title: PROCESS FOR THE PRODUCTION OF 16,17-[(CYCLOHEXYLMETHYLEN)BIS(OXY)]-11,21-DIHY-DROXY-PREGNA-1,4-DIEN-3,20-DION OR ITS 21-ISOBUTYRAT BY TRANSKETALISATION

PROCESS FOR THE PRODUCTION OF 16,17-'(CYCLOHEXYLMETHYLEN)BIS(OXY)!-11, 21-DIHYDROXY-PREGNA-1,4-DIEN-3,20-DION OR ITS 21-ISOBUTYRAT BY TRANSKETALISATION

#### Technical field

The invention relates to a novel process for the preparation of a known glucocorticoid, which is used in the pharmaceutical industry for the production of medicaments.

#### Prior art

The international patent application WO 9422899 describes novel prednisolone derivatives and a process for their preparation. In this process, 16-hydroxyprednisolone is reacted with cyclohexanealdehyde. German patent application DE 41 29 535 discloses novel glucocorticoids and a process for their preparation. The process comprises reacting pregna-1,4-diene-3,20-dione-16,17-dihydroxy compounds, in the form of their 16,17-diester derivatives, with aldehydes (e.g. with cyclohexanealdehyde) to give the desired final products.

#### Description of the invention

The invention relates to a process for the preparation of the compounds of the formula 1,

in which

R is hydrogen (H) or isobutyryl [CO-CH(CH<sub>3</sub>)<sub>2</sub>], in predominantly epimerically pure form.

It has now been found that the compounds of the formula 1 are obtained in a simple manner in good yield and surprisingly high epimeric purity when, rather than the 16,17-dihydroxy compound or the 16,17-diester, the corresponding 16,17-ketal, in particular the 16,17-acetonide derivative, is used as a starting material.

1

The invention thus relates to a process for the preparation of the compounds of the formula 1 in predominantly epimerically pure form, which comprises reacting compounds of the formula 2,

OR
$$CH_3$$

in which

R is hydrogen (H) or isobutyryl [CO-CH(CH<sub>3</sub>)<sub>2</sub>],

R1 is 1-4C-alkyl and

R2 is1-4C-alkyl,

with cyclohexanealdehyde.

Preferably, the process is carried out using those compounds of the formula 2 in which R1 and R2 are in each case methyl (CH<sub>3</sub>).

The reaction is carried out in suitable solvents such as, for example, ethers, e.g. dioxane, diisopropyl ether, esters, e.g. ethyl acetate, halogenated hydrocarbons, e.g. methylene chloride, chloroform, nitrated hydrocarbons, e.g. nitromethane, 2-nitropropane or preferably 1-nitropropane, or without solvents, with addition of catalytic or else relatively large amounts of acid, such as mineral acids, e.g. tetrafluoroboric acid or in particular perchloric acid, or sulfonic acids, in particular methanesulfonic acid, at temperatures of advantageously 0°C to 60°C.

The reaction of the 16-hydroxyprednisolone ketal of the formula 2 with cyclohexanealdehyde normally yields an epimer mixture. Surprisingly, the reaction, however, is controlled according to the invention by means of suitable reaction conditions such that the R-epimer desired and indicated in formula 1 results. According to the invention, "in predominantly epimerically pure form" thus means that the R-epimer (based on the absolute configuration at C-22) in the compound 1 where R = hydrogen (H) results to at least 90%, preferably at least 95%, in particular at least 97%, based on the total yield.

For the predominant preparation of the R-epimer, the following conditions, for example, are preferred: as solvents, halogenated hydrocarbons (such as methylene chloride or chloroform) or nitrated hydrocarbons (such as nitromethane, 2-nitropropane or preferably 1-nitropropane) and, as a catalyst, methanesulfonic acid (at temperatures from 10°C to 40°C) or 35-70% strength, in particular 60-70%

strength, perchloric acid (at temperatures from 0°C to 40°C, preferably 15°C to 30°C, in particular 20°C to 25°C).

If the R-epimer is desired in purer form than is achievable on account of the reaction conditions, suitable separation and purification steps – such as, for example, preparative HPLC, or fractional crystallization such as described in international patent application WO 9809982 – may follow the reaction.

The following example serves to illustrate the invention in greater detail:

#### Example

## 16,17-[(Cyclohexylmethylene)bis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione[11 $\beta$ ,16 $\alpha$ (R)]

20 g of desonide are suspended in 70 ml of 1-nitropropane and treated slowly with ice-cooling with 12.6 ml of 70% strength perchloric acid and 6.6 g of cyclohexanealdehyde. The reaction mixture is stirred overnight at room temperature and then filtered. The filter cake is dissolved in 90 ml of DMF and the solution is added dropwise with stirring to sodium hydrogencarbonate solution. The precipitate is filtered off with suction, washed with water and dried. 19 g of the title compound having an R-/ S-epimer ratio of 97.8 / 2.2 are obtained.

4

#### Patent claims

1. A process for the preparation of the compounds of the formula 1,

in which

R is hydrogen (H) or isobutyryl [CO-CH(CH<sub>3</sub>)<sub>2</sub>], in predominantly epimerically pure form,

which comprises reacting compounds of the formula 2,

$$\begin{array}{c} OR \\ CH_3 \\ O \\ R2 \end{array} \qquad (2)$$

in which

R is hydrogen (H) or isobutyryl [CO-CH(CH<sub>3</sub>)<sub>2</sub>],

R1 is 1-4C-alkyl and

R2 is1-4C-alkyl,

with cyclohexanealdehyde.

- 2. The process as claimed in claim 1, where R is hydrogen (H).
- 3. The process as claimed in claim 1, where R is isobutyryl [CO-CH(CH<sub>3</sub>)<sub>2</sub>].
- 4. The process as claimed in claim 1, where R1 and R2 are in each case methyl (CH<sub>3</sub>).

5. The process as claimed in claim 1, wherein a halogenated or nitrated hydrocarbon is used as a solvent.

- 6. The process as claimed in claim 1, wherein methanesulfonic acid is used as a catalyst.
- 7. The process as claimed in claim 1, wherein perchloric acid is used as a catalyst.
- 8. The process as claimed in claim 1, wherein the reaction is carried out at temperatures between 0°C and 40°C.
- 9. The process as claimed in claim 1 for the preparation of the compound of the formula 1, in which R is hydrogen (H), in over 95 % epimerically pure form, wherein compounds of the formula 2, in which R is hydrogen (H), R1 is methyl (CH3) and R2 is methyl (CH3), are reacted with cyclohexanealdehyde using perchloric acid as a catalyst at temperatures between 0°C and 40°C.

nal Application No PCT/EP 01/12808

A. CLASSIFI	CATION O	F SUBJEC1	MATTER
IPC 7	C07J7	1/00	

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  $IPC \ \ \, 7 \quad \ \ \, C07J$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ .	WO 94 22899 A (BYK GULDEN LOMBERG CHEM FAB; GUTTERER BEATE (DE)) 13 October 1994 (1994-10-13) cited in the application examples 1-16	1-9
Y	WO 98 09982 A (BYK GULDEN LOMBERG CHEM FAB; GUTTERER BEATE (DE)) 12 March 1998 (1998-03-12) examples 1,2	1-9
Υ	EP 0 508 900 A (ROUSSEL UCLAF) 14 October 1992 (1992-10-14) example 1A	1-9
Υ .	EP 0 262 108 A (ASTRA PHARMA PROD) 30 March 1988 (1988-03-30) examples 6-10	1-9

	<i>-/</i>				
X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.				
Special categories of cited documents:  A' document defining the general state of the art which is not considered to be of particular relevance  E' earlier document but published on or after the international filling date  L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  O' document referring to an oral disclosure, use, exhibition or other means  P' document published prior to the international filling date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>				
Date of the actual completion of the international search  4 March 2002	Date of mailing of the international search report  14/03/2002				
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Watchorn, P				

\_ stional Application No PCT/EP 01/12808

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<b>Y</b>	EP 0 164 636 A (SICOR SPA) 18 December 1985 (1985-12-18) page 2, line 11-14; example 1	1-9
<b>Y</b>	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GIMBERT ROURA, JOSE ET AL: "Hydroxyprednisolone butyraldehyde acetal" retrieved from STN Database accession no. 105:97807 XP002168646	1-9
	abstract & ES 527 509 A (LABORATORIOS FRUMTOST-PREM S. A., SPAIN) 1 August 1985 (1985-08-01)	
٠		

formation on patent family members

onal Application No PCT/EP 01/12808

				. 1017 E1	01/ 12000
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9422899	A	13-10-1994	AT	172739 T	15-11-1998
NO JALLUJJ	n	10 10-1334	AU	683463 B2	13-11-1996
•			AU	6538194 A	24-10-1994
			BG.	62491 B1	30-12-1999
			BG	100032 A	31-05-1996
		•	CA	2159627 A1	13-10-1994
			CN	1120339 A ,B	10-04-1996
			CZ	9502529 A3	17-01-1996
			DE	59407183 D1	03-12-1998
		•	DK	701565 T3	12-07-1999
			WO	9422899 A1	13-10-1994
			EΡ	0701565 A1	20-03-1996
			ES	2124884 T3	16-02-1999
			FΙ	954579 A	27-09-1995
			HU	72594 A2	28-05-1996
			JP	8508278 T	03-09-1996
			NO	953861 A	29-09-1995
			NZ	265054 A	22-08-1997
			PL	311474 A1	19-02-1996
			RU	2132854 C1	10-07-1999
			SI	701565 T1	30-04-1999
			SK	122395 A3	10-01-1996
			US	5733901 A	31-03-1998
	Α	12-03-1998	DE	19635498 A1	26-03-1998
			ĀŪ	736840 B2	02-08-2001
			AU	4456797 A	26-03-1998
			CZ	9900727 A3	15-09-1999
			EE	9900079 A	15-10-1999
			WO	9809982 A1	12-03-1998
		•	EP	0929566 A1	21-07-1999
			HU	9904127 A2	28-04-2000
,		•	JP	2000517330 T	26-12-2000
			PL	331699 A1	02-08-1999
EP 0508900	A	14-10-1992	FR	2675146 A1	16-10-1992
	•	•	DE	69227478 D1	10-12-1998
			DE	69227478 T2	02-06-1999
			· EP	0508900 A1	14-10-1992
			HU	212197 B	28-03-1996
			HU	217523 B	28-02-2000
			HU	220086 B	28-10-2001
		,	HU	220081 B	28-10-2001
			ΙE	921130 A1	21-10-1992
		•	JP	3172575 B2	04-06-2001
•			JP	5170788 A	09-07-1993
			US	5434258 A	18-07-1995
			US	5451690 A	19-09-1995
			US	5310896 A	10-05-1994
EP 0262108	A	30-03-1988	AT	70066 T	15-12-1991
			CY	1791 A	20-10-1995
•			DE	3774987 D1	16-01-1992
			EP	0262108 A1	. 20-03-1300
			EP ES	2026576 T3	30-03-1988 01-05-1992
				2026576 T3	
			ES		01-05-1992

information on patent family members

II 1al Application No PCT/EP 01/12808

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0262108	A	<u> </u>	IL	83994	Α	16-02-1992
•			JP	2668000	B2	27-10-1997
•		·	JP	63093795	Α	25-04-1988
•		•	KR	9514460	B1	28-11-1995
		• • • •	บร	4925933	A	15-05-1990
EP 0164636	A	18-12-1985	IT	1196142	В	10-11-1988
		•	ΑT	56725	T	15-10-1990
			CA	1336513	A1 .	01-08-1995
		•	DE	3579750	D1	25-10-1990
	•		DK	243085	A ,B,	12-12-1985
	•		EP	0164636		18-12-1985
•			ES	543499	DO .	01-05-1987
			ES	8705462	A1	16-07-1987
			FI	852093	A ,B,	12-12-1985
			JР	1588637		19-11-1990
		•	JР	2013680		04-04-1990
		,	JP	61040299		26-02-1986
			NO	852327		12-12-1985
			US	4835145		30-05-1989
•			US ·	4695625		22-09-1987
ES 527509	A		NONE			